U.S. flag An official website of the United States government
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Fresenius Medical Care, North America - 04/30/2015
  1. Warning Letters


Fresenius Medical Care, North America

Fresenius Medical Care, North America

United States

Issuing Office:

United States


Department of Health and Human Services' logoDepartment of Health and Human Services

 Food and Drug Administration
Denver District Office
Building 20- Denver Federal Center
P.O. Box 25087
Denver, Colorado 80225-0087
TELEPHONE: 303-236-3000


April 30, 2015

UPS Overnight

Ronald J. Kuerbitz
Chief Executive Officer
Fresenius Medical Care, North America
920 Winter Street
Waltham, MA 02451

Re: DEN-13-10-WL

Dear Mr. Kuerbitz:

The Food and Drug Administration has completed an evaluation of your firm's corrective actions in response to our Warning Letter DEN-13-10-WL, dated March 5, 2013. Based on our evaluation, it appears that you have addressed the violation(s) contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.



LaTonya M. Mitchell
District Director

cc: Matthew E. Wybrow
      Vice President, Quality Systems
      Fresenius Medical Care, North America
      475 West 13th Street
      Ogden, UT 84404-5554

Back to Top